SCHEMBL19780140

SCHEMBL19780140

CCc1cncc(C#N)c1NC(=O)OC

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 2/20 0.38
PDE4B Q07343 2/20 0.38
PDE4C Q08493 2/20 0.38
PDE4D Q08499 2/20 0.38
GAA P10253 2/20 0.35
MAP2K1 Q02750 1/20 0.35
NLRP3 Q96P20 1/20 0.35
PRKCQ Q04759 1/20 0.34
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
ALDH1A1 P00352 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
TSHR P16473 1/20 0.34
RIPK1 Q13546 1/20 0.34
MAPT P10636 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19780141 0.81 MAP2K1 (0.39) GAAMAP2K1PRKCQLMNACYP1A2
SCHEMBL20621262 0.79 RIPK1 (0.34) PDE4APDE4BPDE4CPDE4DGAA
SCHEMBL19880450 0.78 EGFR (0.36) PDE4APDE4BPDE4CPDE4DMAP2K1
SCHEMBL19779564 0.76 PDE4D (0.47) PDE4APDE4BPDE4CPDE4DNLRP3
SCHEMBL21884020 0.76 NLRP3 (0.37) PDE4APDE4BPDE4CPDE4DNLRP3
SCHEMBL7215529 0.70 KDM5A (0.39) LMNAALDH1A1L3MBTL1RIPK1
SCHEMBL10058048 0.70 MEN1 (0.38) PRKCQLMNAALDH1A1L3MBTL1TSHR
SCHEMBL24595124 0.69 KDM5A (0.40) RIPK1
SCHEMBL21718418 0.69 RIPK1 (0.34) RIPK1
SCHEMBL19779742 0.68 CYP2E1 (0.37) GAAALDH1A1L3MBTL1TSHRRIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180016252-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2018-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180016252-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 PDE4A 92/4885PDE4B 113/4885PDE4C 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.